1262279-06-0

Basic information

• Product Name: 1,3-dihydro-1-hydroxy-2,1-benzoxaborole-6-methanamine
• Synonyms: 1,3-dihydro-1-hydroxy-2,1-benzoxaborole-6-methanamine
• CAS NO: 1262279-06-0
• Molecular Formula: C8H10BNO2
• Molecular Weight: 162.9815
• Mol File: 1262279-06-0.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 1,3-dihydro-1-hydroxy-2,1-benzoxaborole-6-methanamine(CAS DataBase Reference)
• NIST Chemistry Reference: 1,3-dihydro-1-hydroxy-2,1-benzoxaborole-6-methanamine(1262279-06-0)
• EPA Substance Registry System: 1,3-dihydro-1-hydroxy-2,1-benzoxaborole-6-methanamine(1262279-06-0)

Safety Data

• Hazardous Substances Data: 1262279-06-0(Hazardous Substances Data)

Usage

Chemical class

Belongs to the class of benzoxaboroles

Composition

Contains boron

Potential application

Anti-fungal agent

Mechanism of action

Inhibits fungal growth by targeting a specific enzyme involved in fungal protein synthesis

Research focus

Explored for potential use in the treatment of neglected tropical diseases such as malaria and Chagas disease

Structural uniqueness

Promising candidate for the development of novel antifungal and anti-parasitic drugs

Upstream product

• 947162-60-9 1-hydroxy-1,3-dihydrobenzo[c][1,2]oxaborole-6-carbonitrile 
• 1393477-24-1 tert-butyl (1-hydroxy-1,3-dihydrobenzo[c][1,2]oxaborol-6-yl)methylcarbamate 

Downstream Products

• 1262278-98-7 C₁₅H₁₃BN₂O₆ 
• 1437049-33-6 4-(5-(3,5-dichlorophenyl)-5-(trifluoromethyl)-4,5-dihydroisoxazol-3-yl)-N-((1-hydroxy-1,3-dihydrobenzo[c][1,2]oxaborol-6-yl)methyl)-2-methylbenzamide 

Relevant articles and documents

Optimization of isoxazoline amide benzoxaboroles for identification of a development candidate as an oral long acting animal ectoparasiticide

Novel isoxazoline amide benzoxaboroles were designed and synthesized to optimize the ectoparasiticide activity of this chemistry series against ticks and fleas. The study identified an orally bioavailable molecule, (S)-N-((1-hydroxy-3,3-dimethyl-1,3-dihydrobenzo[c][1,2]oxaborol-6-yl)methyl)-2-methyl-4-(5-(3,4,5-trichlorophenyl)-5-(trifluoromethyl)-4,5-dihydroisoxazol-3-yl)benzamide (23), with a favorable pharmacodynamics profile in dogs (Cmax = 7.42 ng/mL; Tmax = 26.0 h; terminal half-life t1/2 = 127 h). Compound 23, a development candidate, demonstrated 100% therapeutic effectiveness within 24 h of treatment, with residual efficacy of 97% against American dog ticks (Dermacentor variabilis) on day 30 and 98% against cat fleas (Ctenocephalides felis) on day 32 after a single oral dose at 25 mg/kg in dogs.

BORON CONTAINING POLYBASIC BACTERIAL EFFLUX PUMP INHIBITORS AND THERAPEUTICS USES THEREOF

Disclosed herein are polybasic bacterial efflux pump inhibitors containing boronic acid functionality and theft methods of synthesis, methods of use, and pharmaceutical compositions. Some embodiments include methods of treating or preventing a bacterial infection by co-administering to a subject infected with bacteria or at risk of infection with bacteria the efflux pump inhibitor with another anti-bacterial agent

Synthesis and biological evaluations of P4-benzoxaborole-substituted macrocyclic inhibitors of HCV NS3 protease

We disclose here a series of P4-benzoxaborole-substituted macrocyclic HCV protease inhibitors. These inhibitors are potent against HCV NS3 protease, their anti-HCV replicon potencies are largely impacted by substitutions on benzoxaborole ring system and P2 groups. P2 2-thiazole-isoquinoline provides best replicon potency. The in vitro SAR studies and in vivo PK evaluations of selected compounds are described herein.